CLDX : Summary for Celldex Therapeutics, Inc. - Yahoo Finance

U.S. Markets closed

Celldex Therapeutics, Inc. (CLDX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.41+0.07 (+2.10%)
At close: 4:00PM EST
People also watch
ACADCLVSARRYSRPTSGEN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.34
Open3.35
Bid3.15 x 2500
Ask3.92 x 100
Day's Range3.25 - 3.44
52 Week Range2.85 - 11.37
Volume1,624,605
Avg. Volume2,241,080
Market Cap407.52M
Beta2.82
PE Ratio (TTM)-2.63
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Beaten-Down Biotech Stocks You Can Buy Right Now
    Motley Fool2 days ago

    3 Beaten-Down Biotech Stocks You Can Buy Right Now

    Why Celldex, Geron, and Vertex could be biotech stocks that bounce back in a big way in 2017.

  • Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : January 10, 2017
    Capital Cube12 days ago

    Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : January 10, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Celldex Therapeutics, Inc. a score of 28. Our analysis is based on comparing Celldex Therapeutics, Inc. with the following peers – Seattle Genetics, Inc., Northwest Biotherapeutics, Inc., Emergent BioSolutions Inc., Agenus Inc., GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Vical Incorporated, Bristol-Myers Squibb Company, Pfizer Inc. and CytRx ... Read more (Read more...)

  • Why Celldex Therapeutics Imploded in 2016
    Motley Fool12 days ago

    Why Celldex Therapeutics Imploded in 2016

    A failed trial sent Celldex's shares spiraling downward last year. Can this beaten-down biotech make a comeback in 2017?